Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scios Natrecor

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amendment to the nesiritide NDA is expected to be filed by year's end, according to the firm. In January 1999, FDA's Cardio-Renal Drugs Advisory Committee recommended Natrecor for approval in treating chronic decompensated congestive heart failure, but FDA found the agent "not approvable" in April 1999, saying that further study was needed to "define the consequences of the pharmacodynamic profile." Enrollment has now been completed for the final Phase III, pivotal trial. The 490-patient study, known as the Vasodilation in the Management of Acute Congestive heart failure (VMAC) trial, was designed to "further evaluate the efficacy and safety of Natrecor in acutely ill patients with shortness of breath (dyspnea) at rest due to decompensated CHF," Scios said. An initial analysis of the study is expected to be released in the fal

You may also be interested in...



QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Unilever Hit With Class Action Over Mercury-Laced Pond’s Cream Originating In Mexico

According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.

Topics

UsernamePublicRestriction

Register

PS001158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel